Global Anticoagulation Therapy Market is expected to grow at a substantial CAGR of 8.3% in the forecast period of 2019 to 2026. The years considered for study are as mentioned below.
Access Full Report at https://databridgemarketresearch.com/reports/global-anticoagulation-therapy-market
The anticoagulation therapy market is an upcoming market which includes key players and local players. The market is growing to the favourable market scenario. The market has a prominent growth in upcoming years due to rising prevalence of venous thromboembolism and pulmonary embolism, increasing usage of NOACS as alternatives to warfarin.
The market has witness developments in terms of merger and acquisitions or product launches to enhance the product portfolio to meet the rising demand of dry eye syndrome treatment. For instance, In March 2019, Janssen Pharmaceuticals, Inc. subsidiary of Johnson & Johnson Service, Inc. published real world metaanalysis for 95 studies during investigation of non-vitamin K antagonist oral anticoagulants (NOACs) usage and highlighted that its NOACs XARELTO, usage lowered the chances of ischemic stroke and intracranial hemorrhage (ICH) as compared to warfarin usage. This will help to grow company’s revenue. This will help the company to expand its product portfolio in the market.
Bristol-Myers Squibb Company dominated the global anticoagulation therapy market. The other key players existing in the market Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical（Group）Co., Ltd., Cipla Inc., DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Portola Pharmaceuticals, Inc., Taro Pharmaceutical Industries Ltd., among others.
Bristol-Myers Squibb Company:
Bristol-Myers Squibb Company headquartered in New York, U.S was founded in 1858. The company is focused in the discovery, development, licensing, manufacturing, marketing, distribution and sales of innovative medicines which help the patients prevail over serious diseases. The company is providing Atripla, Azactam, Baraclude, Coumadin, Daklinza, Droxia, Eliquis, Empliciti, Etopophos, Evotaz, Glucophage, Glucovance, Hydrea, Kenalog, Kenalog, Lysodren, Megace, Nulojix, Opdivo, Orencia, Plavix, Pravachol, Reyataz, Sprycel, Sustiva, Videx, Yervoy, Zerit. The market focuses on Coumadin, Eliquis product. The company deals into one business category bio-pharmaceuticals. The company is continuously engaged in developing the anticoagulation therapy for instance,
- In April 2018, Bristol-Myers Squibb Company collaborated with Janssen Pharmaceutical Inc. a subsidiary of Johnson & Johnson Service, Inc. The focus of this collaboration is to commercialize and develop Factor XIa (FXIa) inhibitors, next-generation anticoagulants. This collaboration will help to grow the company’s market presence and will strengthen its portfolio.
The company has wide geographic presence in Asia-Pacific, Europe, Middle East and Africa, South America and North America. It operates through its subsidiaries such as Bristol-Myers Squibb GmbH & Co. KGaA (Germany), Adnexus Therapeutics, Inc. (U.S.), Bristol-Myers Squibb S.L. (Spain), Bristol-Myers Squibb A.E. (Greece), Amira Pharmaceuticals, Inc. (U.S.), among others
Pfizer Inc.:
Pfizer Inc. headquartered in New York, U.S was founded in 1849. The company is engaged in the discovery, development, manufacturing and sales of healthcare products worldwide. The company mainly manages their operation in IH (innovative health segment), EH (essential health segment). The market focus category lies under IH (innovative health segment). The company is continuously engaged in developing the anticoagulation therapy drug for instance-
- In May 2019, Pfizer Inc. received the FDA Approval for Fragmin. It is a first approval for anticoagulant to treat pediatric patients from potentially lifethreatening blood clots. This approval will help company to grow its anticoagulant portfolio and will help to lead the market in anticoagulant therapy as it is first of its kind.
The company has wide geographical presence in Asia-Pacific, Europe, Middle East and Africa, South America and North America. It operates through its subsidiaries such as Warner-Lambert Company LLC (U.S.), Pfizer Enterprises SARL (Luxembourg), Pfizer Luxembourg SARL (Luxembourg), Pfizer Investment Co. Ltd. (China), Wyeth Lederle S.p.A. (Italy), among others.
Bayer AG:
Bayer AG headquartered in Leverkusen, Germany was founded in 1863. The company focuses on the areas of health care and agriculture. The company operates in pharmaceuticals, consumer health, crop science, animal health, reconciliation. The market focus category lies under pharmaceuticals. The company has product in operates in Pharmaceuticals, Consumer Health, Crop Science, Animal Health. The market focus category lies under pharmaceuticals. The company is continuously engaged in developing the anticoagulation therapy for instance-
- In August 2018, Bayer AG received the European Commission (EC) approval for Xarelto (rivaroxaban) 2.5 mg. It is indicated for reduction of chances of cardiovascular situations such as stroke/ heart attack in patients with chronic coronary artery disease (CAD), cardiovascular (CV) death, and peripheral artery disease (PAD). This approval will help the company to develop anticoagulant business in European countries.
The company has wide geographical presence in Asia-Pacific, Europe, Middle East and Africa, South America and North America. The company has various subsidiaries such as Bayer HealthCare Pharmaceuticals LLC (Germany), Jenapharm GmbH & Co. KG (Germany), Bayer Healthcare (Germany), Bayer Ltd. (Ukraine), Bayer HealthCare Animal Health Inc. (U.S.), among others.
